Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DKd regimen in non-transplant newly diagnosed multiple myeloma
ChiCTR2500095766Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Kunming Medical University
- Start
- Jan 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of daratumumab, carfilzomib and dexamethasone in multiple myeloma (MM), sponsored by First Affiliated Hospital of Kunming Medical University. Primary endpoint: Objective Response Rate. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
daratumumabcarfilzomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2500095766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095766.